List of works - Vanita R Aroda

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice

scientific article published on 29 January 2020

A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

scientific article

Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

scientific article published on 07 August 2019

Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts

scientific article published on 25 June 2018

Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy

scientific article published on 20 August 2020

Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists (GLP-1RAs): a systematic literature review and indirect treatment comparison

scientific article published on 06 July 2020

Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements

scientific article published on 24 July 2018

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

scientific article published on 17 September 2019

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus GLP-1 RAs in people with type 2 diabetes mellitus: a network meta-analysis

scientific article published on 29 September 2020

Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials

scientific article published on 14 November 2019

Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial

scientific article published on 23 April 2020

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses

scientific article published on 16 November 2020

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

scientific article published on 30 June 2019

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

scientific article published on 01 April 2018

Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight

scientific article published on 05 March 2020

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

scientific article published on 11 June 2019

Response to Letter to the Editor: "Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program"

scientific article published on 01 May 2018

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial